4//SEC Filing
Versant Ventures VI GP-GP, LLC 4
Accession 0001104659-20-001732
CIK 0001744659other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 8:59 PM ET
Size
34.6 KB
Accession
0001104659-20-001732
Insider Transaction Report
Form 4
Versant Venture Capital VI, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-01-02$22.17/sh−1,000$22,170→ 3,996,859 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$19.89/sh−10,952$217,835→ 4,001,759 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$21.20/sh−3,900$82,680→ 3,997,859 total(indirect: See footnote) - Other
Common Stock
2020-01-02−684,143→ 3,312,716 total(indirect: See footnote) - Other
Common Stock
2020-01-02+13,683→ 13,683 total(indirect: See footnote) - Other
Common Stock
2020-01-02−13,683→ 0 total(indirect: See footnote) - Other
Common Stock
2020-01-02+11,803→ 11,803 total(indirect: See footnote) - Other
Common Stock
2020-01-02−11,803→ 0 total(indirect: See footnote) - Sale
Common Stock
2020-01-03$19.18/sh−3,100$59,458→ 3,309,616 total(indirect: See footnote) - Sale
Common Stock
2020-01-03$20.27/sh−100$2,027→ 3,309,516 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$17.68/sh−4,968$87,834→ 3,304,548 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$18.32/sh−6,101$111,770→ 3,298,447 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$19.93/sh−42,323$843,497→ 3,256,124 total(indirect: See footnote)
Versant Ventures VI GP, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-01-02$21.20/sh−3,900$82,680→ 3,997,859 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$22.17/sh−1,000$22,170→ 3,996,859 total(indirect: See footnote) - Other
Common Stock
2020-01-02+13,683→ 13,683 total(indirect: See footnote) - Other
Common Stock
2020-01-02−13,683→ 0 total(indirect: See footnote) - Other
Common Stock
2020-01-02+11,803→ 11,803 total(indirect: See footnote) - Other
Common Stock
2020-01-02−11,803→ 0 total(indirect: See footnote) - Sale
Common Stock
2020-01-03$20.27/sh−100$2,027→ 3,309,516 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$19.89/sh−10,952$217,835→ 4,001,759 total(indirect: See footnote) - Other
Common Stock
2020-01-02−684,143→ 3,312,716 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$17.68/sh−4,968$87,834→ 3,304,548 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$18.32/sh−6,101$111,770→ 3,298,447 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$19.93/sh−42,323$843,497→ 3,256,124 total(indirect: See footnote) - Sale
Common Stock
2020-01-03$19.18/sh−3,100$59,458→ 3,309,616 total(indirect: See footnote)
Versant Ventures VI GP-GP, LLC
10% Owner
Transactions
- Other
Common Stock
2020-01-02−684,143→ 3,312,716 total(indirect: See footnote) - Other
Common Stock
2020-01-02+13,683→ 13,683 total(indirect: See footnote) - Other
Common Stock
2020-01-02+11,803→ 11,803 total(indirect: See footnote) - Other
Common Stock
2020-01-02−11,803→ 0 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$19.89/sh−10,952$217,835→ 4,001,759 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$21.20/sh−3,900$82,680→ 3,997,859 total(indirect: See footnote) - Sale
Common Stock
2020-01-02$22.17/sh−1,000$22,170→ 3,996,859 total(indirect: See footnote) - Other
Common Stock
2020-01-02−13,683→ 0 total(indirect: See footnote) - Sale
Common Stock
2020-01-03$19.18/sh−3,100$59,458→ 3,309,616 total(indirect: See footnote) - Sale
Common Stock
2020-01-03$20.27/sh−100$2,027→ 3,309,516 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$17.68/sh−4,968$87,834→ 3,304,548 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$18.32/sh−6,101$111,770→ 3,298,447 total(indirect: See footnote) - Sale
Common Stock
2020-01-06$19.93/sh−42,323$843,497→ 3,256,124 total(indirect: See footnote)
Footnotes (17)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
- [F10]The shares are held by Versant GP LLC.
- [F11]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LLC without consideration to its members.
- [F12]These sales were executed in multiple trades at prices ranging from $19.00 to $19.48. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F13]These sales were executed in multiple trades at prices ranging from $20.25 to $20.32. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F14]These sales were executed in multiple trades at prices ranging from $17.00 to $17.98. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F15]These sales were executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F16]These sales were executed in multiple trades at prices ranging from $19.55 to $20.22. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F17]These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein.
- [F2]These sales were executed in multiple trades at prices ranging from $19.56 to $20.26. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F3]These sales were executed in multiple trades at prices ranging from $20.87 to $21.56. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F4]These sales were executed in multiple trades at prices ranging from $22.00 to $22.25. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F5]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital VI, L.P. ("Versant VI") without consideration to its partners.
- [F6]Represents a change in the form of ownership of Versant Ventures VI GP, LP ("Versant GP LP") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant VI.
- [F7]The shares are held by Versant GP LP. Versant GP LLC is the general partner of Versant GP LP and may be deemed to have voting and investment power over the securities held by Versant GP LP and as a result may be deemed to have beneficial ownership over such securities. Versant GP LLC disclaims beneficial ownership over these securities except to the extent of its pecuniary interest therein.
- [F8]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LP without consideration to its partners.
- [F9]Represents a change in the form of ownership of Versant Ventures VI GP-GP, LLC ("Versant GP LLC") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant GP LP.
Documents
Issuer
Akero Therapeutics, Inc.
CIK 0001744659
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001777652
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 8:59 PM ET
- Size
- 34.6 KB